Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-201 in autoimmune diseases
NCT07732309Phase 1Recruiting
- Sponsor
- Antengene
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATG-201 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome and 1 more, sponsored by Antengene. Primary endpoint: Safety and Tolerability at 48 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ATG-201
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Sjögren's syndromeautoimmune disease
Beyond the preview
Go deeper on NCT07732309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732309.